Prognostic value of  FOXA1 expression in urinary bladder cancer

Rasha  Ali Akar; Hameed Naeem Mousa; Satar Abood Faris

doi:10.32792/jeps.v13i3.366

المؤلفون

Rasha Ali Akar
Hameed Naeem Mousa
Satar Abood Faris

DOI:

https://doi.org/10.32792/jeps.v13i3.366

الملخص

The aim of currentstudy was to determine the expression of the FOXA1 protein in human bladder cancer, and demonstration of correlations between this parameters and clinical pathologic variables as grade and stage of tumour,non muscle invasive tumour and also by using this marker can classify bladder cancer in to basal and luminal type. The Current study is designed to detect the role of FOXA1expression in bladder carcinoma as a possible marker for detecting the biological behaviour of malignancy and its correlation with grade and muscle invasiveness for both diagnostic and prognostic purposes. The Current study focuses on a technique of immunohistochemistry for detection FOXA1expression in bladder cancer. The samples are collected randomly in southern Iraq in AL- Nasiriya city from AL Hussein teaching hospital. Number of samples is (100) of bladder tissue, ( 70)of bladder cancer tissue and (30) controls benign tissue. Results of this study reveal that FOXA1 expression is positive in( 29) out of (70) sample. The study approves that FOXA1 expressed was increased in low grade bladder cancer( 63.6%), FOXA1 expression high in the early tumour stage as (Ta) stage (94.7%), FOXA1 expression was high in non-muscle invasive (85.7%) ,FOXA1 has also shown an increase in male with bladder cancer represent (51.1).
So FOXA1can be used as a marker for assessment of bladder cancer aggressiveness. This study represents an important first step in Thi-qar because there are absence of a studies about this topic which to highlights this tumour and divides in to two types luminal and basal

المراجع

Richters, A.; Aben, K.K.H. and Kiemeney, L. (2020). The global burden of urinary bladder cancer: An update. World J. Urol., 38, PP: 1895–1904.

Lenis, A.T.; Lec, P.M.; Chamie, K.; and Mshs, M.D. (2020). Bladder Cancer A Review. JAMA, 324,PP: 1980–1991.

-Miremani, J. and N. Kyprianou (2014). The promise of novel molecular markers in bladder cancer. In J mol sci.,15(12); PP:23897-23899.

-,. Global Cancer Observatory.(2020). Estimated age-standardized incidence rates (World) in 2020, worldwide, both sexes, all ages. 2020;2020.

- Rosenberg J.E; Hoffman-Censits J, Powles T, van der Heijden MS, AV, and Necchi A,(2020).Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre، phase 2 trial. Lancet. 387; PP:1909–1920.

-Babjuk, M.; Burger, M. and Zigeuner, R. (2013). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update. Eur Urol., 64; PP:639-653.

- Iraqi Cancer Registry(2011) Baghdad-Iraq. 8- Iraqi Cancer Registry(2021) Baghdad-Iraq.

-McConkey, D. J. and Choi, W. (2018). Molecular subtypes of bladder cancer. Curr. Oncol. Rep; PP: 20-27.

-Gakis, G. (2020). Management of muscle-invasive bladder cancer: Challenges and perspectives. Eur. Urol. Focus 6; PP: 632–638.

-Flaig, T. W. (2020). Bladder cancer, version, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 18; PP: 329–354.

-Bejrananda,T.;Pripatnanont,C.;Tanthanuch,M.and Karnjanawanichkul, W. (2017). Oncological outcomes of radical cystectomy for transitional cell carcinoma of bladder. J. Med. Assoc. Thai. 100; PP: 24–32.

-Bernardo, G. M. and Keri, R. A. (2012). FOXA1 a transcription factor with parallel functions in development and cancer. Bioscience reports, 32(2); PP: 113-130.

-Wolf, I., Bose, S., Williamson, E. A., Miller, C. W., Karlan, B. Y., and Koeffler, H. P. (2007). FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. International journal of cancer, 120(5), 1013-1022.

-Teng, M., Zhou, S., Cai, C., Lupien, M., and He, H. H. (2021). Pioneer of prostate cancer: past, present and the future of FOXA1. Protein & Cell, 12(1), 29-38

-Coons, AH., Creech, HJ., and Jones, RN. (1941). Immunological properties of an antibody containing a fluorescent group. ExpBiol Med 47: 200-202.

- De-Graff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, et al. (2012). Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation. PLoS ONE 7(5)

-Raman, J. D., Warrick, J. I., Caruso, C., Yang, Z., Shuman, L., Bruggeman, R. D., and DeGraff, D. J. (2016). Altered expression of the transcription factor forkhead box A1 (FOXA1) is associated with poor prognosis in urothelial carcinoma of the upper urinary tract. Urology, 94, 314-e1.

-Augello M.A, Hickey T.E, and Knudsen K.E (2011). FOXA1: master of steroid receptor function in cancer. The EMBO journal 30: 3885–3894.